ATB200 + AT2221
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pompe Disease Infantile-Onset
Conditions
Pompe Disease Infantile-Onset
Trial Timeline
— → —
NCT ID
NCT04327973About ATB200 + AT2221
ATB200 + AT2221 is a pre-clinical stage product being developed by Amicus Therapeutics for Pompe Disease Infantile-Onset. The current trial status is active. This product is registered under clinical trial identifier NCT04327973. Target conditions include Pompe Disease Infantile-Onset.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04327973 | Pre-clinical | Active |
| NCT03865836 | Pre-clinical | Active |
| NCT02675465 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pompe Disease Infantile-Onset
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S-606001 + Placebo | Shionogi | Phase 2 | 52 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| GZ402666 | Sanofi | Phase 1 | 32 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| glucosidase alfa | Sanofi | Pre-clinical | 22 |
| Alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 51 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 76 |
| Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) | Sanofi | Approved | 84 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 84 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| recombinant human acid alpha-glucosidase (rhGAA) | Sanofi | Phase 2 | 51 |